Heron Therapeutics (HRTX) PT Raised to $46 at Leerink Partners; 'Focus Moving to HTX-011's Commercialization'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts HRTX Hot Sheet
Price: $0.30 --0%
Rating Summary:
17 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
17 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Leerink Partners raised its price target on Heron Therapeutics (NASDAQ: HRTX) to $46.00 (from $36.00) while maintaining a Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades Goldman Sachs (GS) to Buy
- Pinnacle Financial Partners (PNFP) PT Raised to $115 at DA Davidson
- Waste Connections Inc. (WCN) PT Raised to $206 at BMO Capital
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
